a Department of Psychiatry, Social Psychiatry and Psychotherapy, Division of Clinical Psychology and Sexual Medicine , Hannover Medical School , Hannover , Germany.
Expert Opin Pharmacother. 2018 Oct;19(15):1705-1709. doi: 10.1080/14656566.2018.1525359. Epub 2018 Sep 21.
Persistent genital arousal disorder (PGAD) is a presumably rare, although debilitating condition, which was first defined only at the beginning of this century and has not yet found consideration by any of the international classification systems of diseases. As affected patients can suffer tremendously, this report aims at providing an overview and an expert opinion on the few existing studies and case reports, guiding clinicians in the treatment and pharmacotherapy of PGAD. Areas covered: In this article case reports, case series and surveys on drugs that may both alleviate or worsen/induce PGAD are reported. Expert opinion: Data on pharmacological treatment options in PGAD are sparse and mainly rely on case reports making conclusions difficult. Most importantly, some drugs such as serotonin reuptake inhibitors (SSRIs) may even induce or worsen PGAD during treatment or withdrawal. We now need an initial spark in order to promote basic research on the etiology of PGAD as well as clinical trials on possible treatment options. In the meanwhile, clinicians should provide careful diagnostics and counseling for affected patients. In case pharmacotherapy is desired, drugs that are able to inhibit sexual excitation and/or modulate sensory perception such as pregabalin or duloxetin might be worth a trial.
持续性生殖器觉醒障碍（PGAD）是一种罕见的、但使人虚弱的疾病，尽管它在本世纪初才被首次定义，但尚未被任何国际疾病分类系统所考虑。由于受影响的患者可能会遭受极大的痛苦，因此，本报告旨在对现有的少数研究和病例报告进行概述和专家意见，为临床医生提供 PGAD 的治疗和药物治疗方面的指导。涵盖领域：本文报告了可能缓解或加重/诱导 PGAD 的药物的病例报告、病例系列和调查。专家意见：PGAD 的药物治疗选择的数据很少，主要依赖于病例报告，这使得结论难以得出。最重要的是，一些药物，如 5-羟色胺再摄取抑制剂（SSRIs），甚至可能在治疗或停药期间诱发或加重 PGAD。我们现在需要一个初步的契机，以促进对 PGAD 病因的基础研究以及对可能的治疗选择的临床试验。在此期间，临床医生应为受影响的患者提供仔细的诊断和咨询。如果需要药物治疗，具有抑制性兴奋和/或调节感觉感知能力的药物，如普瑞巴林或度洛西汀，可能值得一试。
